Uzedy is a drug owned by Teva Neuroscience Inc. It is protected by 9 US drug patents filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 05, 2033. Details of Uzedy's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9023897 | Biodegradable drug delivery compositions |
Apr, 2033
(8 years from now) | Active |
| US8741327 | Method of maintaining therapeutic risperidone levels in a PLA:PLGA implant |
Nov, 2027
(2 years from now) | Active |
| US8221778 | Drug-containing implants and methods of use thereof |
Nov, 2027
(2 years from now) | Active |
| US9925268 | Drug-containing implants and methods of use thereof |
Jan, 2025
(a month from now) | Active |
| US9717799 | Drug-containing implants and methods of use thereof |
Jan, 2025
(a month from now) | Active |
| US10736965 | Risperidone biodegradable implant |
Jan, 2025
(a month from now) | Active |
| US8802127 | Risperidone-containing PLA:PGA implants and methods of use thereof |
Jan, 2025
(a month from now) | Active |
| US9895447 | Drug-containing PLA implants and methods of use thereof |
Jan, 2025
(a month from now) | Active |
| US9439905 | Risperidone-containing implants and methods of use thereof |
Jan, 2025
(a month from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Uzedy's patents.
Latest Legal Activities on Uzedy's Patents
Given below is the list of recent legal activities going on the following patents of Uzedy.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Surcharge for Late Payment, Large Entity | 17 Apr, 2024 | US10736965 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Apr, 2024 | US10736965 |
| Maintenance Fee Reminder Mailed Critical | 01 Apr, 2024 | US10736965 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Feb, 2024 | US9439905 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 03 Jan, 2024 | US8221778 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 02 Nov, 2022 | US9023897 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 26 Jan, 2022 | US8802127 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Sep, 2021 | US9925268 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 04 Aug, 2021 | US9895447 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Jan, 2021 | US9717799 |
FDA has granted several exclusivities to Uzedy. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Uzedy, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Uzedy.
Exclusivity Information
Uzedy holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Uzedy's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 28, 2026 |
US patents provide insights into the exclusivity only within the United States, but Uzedy is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Uzedy's family patents as well as insights into ongoing legal events on those patents.
Uzedy's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Uzedy's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 05, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Uzedy Generic API suppliers:
Risperidone is the generic name for the brand Uzedy. 39 different companies have already filed for the generic of Uzedy, with Heritage Pharma Avet having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Uzedy's generic
Alternative Brands for Uzedy
Uzedy which is used for managing symptoms of schizophrenia., has several other brand drugs in the same treatment category and using the same active ingredient (Risperidone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Alkermes Inc |
| |||||||||
| Indivior |
| |||||||||
| Intra-cellular |
| |||||||||
| Janssen Pharms |
| |||||||||
| Otsuka |
| |||||||||
| Otsuka Pharm Co Ltd |
| |||||||||
| Sunovion Pharms Inc |
| |||||||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Risperidone. Given below is the list of those drugs and companies owning them.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Risperidone, Uzedy's active ingredient. Check the complete list of approved generic manufacturers for Uzedy
About Uzedy
Uzedy is a drug owned by Teva Neuroscience Inc. It is used for managing symptoms of schizophrenia. Uzedy uses Risperidone as an active ingredient. Uzedy was launched by Teva in 2023.
Approval Date:
Uzedy was approved by FDA for market use on 28 April, 2023.
Active Ingredient:
Uzedy uses Risperidone as the active ingredient. Check out other Drugs and Companies using Risperidone ingredient
Treatment:
Uzedy is used for managing symptoms of schizophrenia.
Dosage:
Uzedy is available in suspension, extended release form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 50MG/0.14ML (50MG/0.14ML) | SUSPENSION, EXTENDED RELEASE | Prescription | SUBCUTANEOUS |
| 100MG/0.28ML (100MG/0.28ML) | SUSPENSION, EXTENDED RELEASE | Prescription | SUBCUTANEOUS |
| 75MG/0.21ML (75MG/0.21ML) | SUSPENSION, EXTENDED RELEASE | Prescription | SUBCUTANEOUS |
| 200MG/0.56ML (200MG/0.56ML) | SUSPENSION, EXTENDED RELEASE | Prescription | SUBCUTANEOUS |
| 125MG/0.35ML (125MG/0.35ML) | SUSPENSION, EXTENDED RELEASE | Prescription | SUBCUTANEOUS |
| 250MG/0.7ML (250MG/0.7ML) | SUSPENSION, EXTENDED RELEASE | Prescription | SUBCUTANEOUS |
| 150MG/0.42ML (150MG/0.42ML) | SUSPENSION, EXTENDED RELEASE | Prescription | SUBCUTANEOUS |